Loading organizations...
§ Private Profile · Houston, TX, USA
AI diagnostics company developing machine learning algorithms for healthcare providers, focused on early detection of critical conditions.
Oakland, California-based Dascena develops machine learning algorithms designed for the early detection of critical medical conditions such as sepsis and acute kidney injury across healthcare providers and hospital systems. Prior to its 2022 acquisition by CirrusDx, the digital health firm reached over one million patients, generated an estimated $5.1 million in annual revenue, and maintained a workforce of 48 employees. The enterprise secured $50.2 million in total venture capital funding, highlighted by a $50 million Series B round led by Frazier Healthcare Partners, with additional participation from Longitude Capital and Euclidean Capital. Dascena also partnered with Johnson & Johnson to develop a pulmonary hypertension algorithm and received FDA Breakthrough Device Designation for its gastrointestinal bleed risk prediction tool. Operating an additional laboratory facility in Houston, Texas, Dascena was founded in 2017 by Ritankar Das.
Dascena has raised $50.0M across 1 funding round.
Dascena has raised $50.0M in total across 1 funding round.
Dascena has raised $50.0M across 1 funding round. Most recently, it raised $50.0M Series B in April 2020.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Apr 30, 2020 | $50M Series B | Frazier Healthcare Partners | Euclidean Capital, Longitude Capital | Announced |
Dascena has raised $50.0M in total across 1 funding round.
Dascena's investors include Frazier Healthcare Partners, Euclidean Capital, Longitude Capital.